Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis

References

• World Health Organisation. WHO Coronavirus (COVID-19) Dashboard [Internet]. [cited 2023 Apr 26]. Available from: https://covid19.who.int/
   Google Scholar
• Watson OJ, Barnsley G, Toor J, et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293–1302. doi: 10.1016/S1473-3099(22)00320-6
   PubMed Web of Science ®Google Scholar
• World Health Organisation. COVID-19 vaccine tracker and landscape [internet]. [cited 2023 Apr 26]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
   Google Scholar
• UNICEF. COVID-19 Market Dashboard [Internet]. [cited 2023 Apr 26]. Available from: https://www.unicef.org/supply/covid-19-market-dashboard
   Google Scholar
• Sutton N, San Francisco Ramos A, Beales E, et al. Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis. Expert Rev Vaccines. 2022;21(9):1301–1318. doi: 10.1080/14760584.2022.2098719
   PubMed Web of Science ®Google Scholar
• Shaw RH, Stuart A, Greenland M, et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397(10289):2043–2046. doi: 10.1016/S0140-6736(21)01115-6
   PubMed Web of Science ®Google Scholar
• Atmar RL, Lyke KE, Deming ME, et al. Homologous and heterologous COVID-19 booster vaccinations. N Engl J Med. 2022;386(11):1046–1057. doi: 10.1056/NEJMoa2116414
   PubMed Web of Science ®Google Scholar
• Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic covid-19 infection in Sweden: a nationwide cohort study. Lancet Reg Health Eur. 2021;11:100249. doi: 10.1016/j.lanepe.2021.100249
   PubMedGoogle Scholar
• Goncu Ayhan S, Oluklu D, Atalay A, et al. COVID‐19 vaccine acceptance in pregnant women. Int J Gynecol Obst. 2021;154(2):291–296. doi: 10.1002/ijgo.13713
   PubMed Web of Science ®Google Scholar
• Patterson L, Berry E, Parsons C, et al. Using the COM-B framework to elucidate facilitators and barriers to COVID-19 vaccine uptake in pregnant women: a qualitative study. BMC Pregnancy Childbirth. 2023;23(1):640. doi: 10.1186/s12884-023-05958-y
   PubMed Web of Science ®Google Scholar
• Tse A, Tseng HF, Greene SK, et al. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the vaccine safety datalink project, 2010–2011. Vaccine. 2012;30(11):2024–2031. doi: 10.1016/j.vaccine.2012.01.027
   PubMed Web of Science ®Google Scholar
• Duffy J, Hambidge SJ, Jackson LA, et al. Febrile seizure risk after vaccination in children one to five months of age. Pediatr Neurol. 2017;76:72–78. doi: 10.1016/j.pediatrneurol.2017.08.005
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. doi: 10.1186/s13643-021-01626-4
   PubMed Web of Science ®Google Scholar
• Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. doi: 10.1186/s13643-016-0384-4
   PubMedGoogle Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019:l4898. doi: 10.1136/bmj.l4898
   PubMed Web of Science ®Google Scholar
• Rohatgi A. WebPlotdigitizer [Internet]. [cited 2023 Apr 26]. Available from: https://automeris.io/WebPlotDigitizer
   Google Scholar
• Higgins JPT, Thomas J, Chandler J, (editors). Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane; 2023.
   Google Scholar
• Mathieu E, Ritchie H, Rodés-Guirao L, et al. Coronavirus pandemic (COVID-19) [internet]. Our World In Data. 2020 [cited 2023 Apr 26]. Available from: https://ourworldindata.org/coronavirus
   Google Scholar
• Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi: 10.1136/bmj.327.7414.557
   PubMed Web of Science ®Google Scholar
• Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical prediction modelling. Fam Med Com Health. 2020;8(1):8. doi: 10.1136/fmch-2019-000262
   Web of Science ®Google Scholar
• Ahi M, Hamidi Farahani R, Basiri P, et al. Comparison of the safety and immunogenicity of FAKHRAVAC and BBIBP-CorV vaccines when administrated as booster dose: a parallel two arms, randomized, double blind clinical trial. Vaccines (Basel) [Internet]. 2022;10(11):1800. doi: 10.3390/vaccines10111800
   PubMed Web of Science ®Google Scholar
• Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med [Internet]. 2021;385(13):1244–1246. doi: 10.1056/NEJMc2111462
   PubMed Web of Science ®Google Scholar
• Hannawi S, Saifeldin L, Abuquta A, et al. Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial. EBioMedicine [Internet]. 2023;87:104386. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2352396422005680
   PubMed Web of Science ®Google Scholar
• Kumar D, Ferreira VH, Hall VG, et al. Neutralization of SARS-CoV-2 variants in transplant recipients after two and three doses of mRNA-1273 vaccine. Ann Intern Med [Internet]. 2022;175(2):226–233. doi: 10.7326/M21-3480
   PubMed Web of Science ®Google Scholar
• Moreira ED, Kitchin N, Xu X, et al. Safety and efficacy of a third dose of BNT162b2 covid-19 vaccine. N Engl J Med [Internet]. 2022;386(20):1910–1921. doi: 10.1056/NEJMoa2200674
   PubMed Web of Science ®Google Scholar
• Reindl-Schwaighofer R, Heinzel A, Mayrdorfer M, et al. Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients. JAMA Intern Med [Internet]. 2022;182(2):165. doi: 10.1001/jamainternmed.2021.7372
   PubMed Web of Science ®Google Scholar
• Tabarsi P, Anjidani N, Shahpari R, et al. Immunogenicity and safety of spikoGen®, an adjuvanted recombinant SARS‐CoV‐2 spike protein vaccine as a homologous and heterologous booster vaccination: a randomized placebo‐controlled trial. Immunology [Internet]. 2022;167(3):340–353. doi: 10.1111/imm.13540
   PubMed Web of Science ®Google Scholar
• Wang XY, Mahmood SF, Jin F, et al. Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial. Emerg Microbes Infect. 2022;11(1):1910–1919. doi: 10.1080/22221751.2022.2088406
   PubMed Web of Science ®Google Scholar
• Mok CKP, Chen C, Yiu K, et al. A randomized clinical trial using CoronaVac or BNT162b2 vaccine as a third dose in adults vaccinated with two doses of CoronaVac. Am J Respir Crit Care Med [Internet]. 2022;205(7):844–847. doi: 10.1164/rccm.202111-2655LE
   PubMed Web of Science ®Google Scholar
• Intapiboon P, Seepathomnarong P, Ongarj J, et al. Immunogenicity and safety of an intradermal BNT162b2 mRNA vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population. Vaccines (Basel) [Internet]. 2021;9(12):1375. doi: 10.3390/vaccines9121375
   PubMed Web of Science ®Google Scholar
• Shinkai M, Sonoyama T, Kamitani A, et al. Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: an interim report of phase 2/3, randomized, observer-blinded, noninferiority study. Vaccine [Internet]. 2022;40(32):4328–4333. doi: 10.1016/j.vaccine.2022.06.032
   PubMed Web of Science ®Google Scholar
• Nantanee R, Jantarabenjakul W, Jaru-Ampornpan P, et al. A randomized clinical trial of a fractional low dose of BNT162b2 booster in adults following AZD1222. Vaccines (Basel) [Internet]. 2022;10(6):914. doi: 10.3390/vaccines10060914
   PubMed Web of Science ®Google Scholar
• Launay O, Cachanado M, Luong Nguyen LB, et al. Immunogenicity and safety of beta-adjuvanted recombinant booster vaccine. N Engl J Med [Internet]. 2022;387(4):374–376. doi: 10.1056/NEJMc2206711
   PubMed Web of Science ®Google Scholar
• Munro APS, Feng S, Janani L, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis [Internet]. 2022;22(8):1131–1141. doi: 10.1016/S1473-3099(22)00271-7
   PubMed Web of Science ®Google Scholar
• Poh XY, Tan CW, Lee IR, et al. Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial. Clinl Infect Dis [Internet]. 2022;75(12):2088–2096. doi: 10.1093/cid/ciac345
   PubMed Web of Science ®Google Scholar
• Bonelli M, Mrak D, Tobudic S, et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Ann Rheum Dis [Internet]. 2022;81(5):687–694. doi: 10.1136/annrheumdis-2021-221558
   PubMed Web of Science ®Google Scholar
• Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet [Internet]. 2021;398(10318):2258–2276. doi: 10.1016/S0140-6736(21)02717-3
   PubMed Web of Science ®Google Scholar
• Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet [Internet]. 2022;399(10324):521–529. doi: 10.1016/S0140-6736(22)00094-0
   PubMed Web of Science ®Google Scholar
• Chuang C-H, Huang C-G, Huang C-T, et al. Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: a single-blinded, randomized clinical trial. J Clin Virol [Internet]. 2022;157:105328. doi: 10.1016/j.jcv.2022.105328
   PubMed Web of Science ®Google Scholar
• Mallory RM, Formica N, Pfeiffer S, et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis [Internet]. 2022;22(11):1565–1576. doi: 10.1016/S1473-3099(22)00420-0
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ma X, Yan G, et al. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: a randomised, double-blinded, placebo-controlled, phase 2 trial. EClinicalMedicine [Internet]. 2022;54:101680. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2589537022004102
   PubMedGoogle Scholar
• Jin P, Guo X, Chen W, et al. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (convidecia/ZF2001): a randomized, observer-blinded, placebo-controlled trial. Beeson JG, editor. PLoS Med [Internet]. 2022;19(5):e1003953. doi: https://doi.org/10.1371/journal.pmed.1003953
   PubMed Web of Science ®Google Scholar
• Al Kaabi N, Yang YK, Du LF, et al. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. Nat Commun [Internet]. 2022;13(1):3654. doi: 10.1038/s41467-022-31379-0
   PubMed Web of Science ®Google Scholar
• Li J, Hou L, Guo X, et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med [Internet]. 2022;28(2):401–409. doi: 10.1038/s41591-021-01677-z
   PubMed Web of Science ®Google Scholar
• Nanthapisal S, Puthanakit T, Jaru-Ampornpan P, et al. A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines. Vaccine [Internet]. 2022;40(18):2551–2560. doi: 10.1016/j.vaccine.2022.03.036
   PubMed Web of Science ®Google Scholar
• Omma A, Batirel A, Aydin M, et al. Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: a randomized trial. Hum Vaccin Immunother [Internet]. 2022;18(6). doi: 10.1080/21645515.2022.2122503
   PubMed Web of Science ®Google Scholar
• Sablerolles RSG, Rietdijk WJR, Goorhuis A, et al. Immunogenicity and reactogenicity of vaccine boosters after Ad26.COV2.S Priming. N Engl J Med [Internet]. 2022;386(10):951–963. doi: 10.1056/NEJMoa2116747
   PubMed Web of Science ®Google Scholar
• Zhang Z, He Q, Zhao W, et al. A heterologous V-01 or variant-matched bivalent V-01D-351 booster following primary series of inactivated vaccine enhances the neutralizing capacity against SARS-CoV-2 delta and omicron strains. J Clin Med. 2022;11(14):11. doi: 10.3390/jcm11144164
   Web of Science ®Google Scholar
• Graña C, Ghosn L, Evrenoglou T, et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. John Wiley and Sons Ltd; 2022.
   Web of Science ®Google Scholar
• Petrelli F, Luciani A, Borgonovo K, et al. Third dose of SARS-CoV-2 vaccine: a systematic review of 30 published studies. J Med Virol. 2022;94(6):2837–2844. doi: 10.1002/jmv.27644
   PubMed Web of Science ®Google Scholar
• Deng J, Ma Y, Liu Q, et al. Comparison of the effectiveness and safety of heterologous booster doses with homologous booster doses for SARS-CoV-2 vaccines: a systematic review and meta-analysis. Int J Environ Res Public Health MDPI. 2022;19(17):10752. doi: 10.3390/ijerph191710752
   PubMed Web of Science ®Google Scholar
• Office for National Statistics (ONS). COVID-19 vaccine refusal, UK: February to March 2021. [Internet] 2021 [cited 2023 Dec 18]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandwellbeing/bulletins/covid19vaccinerefusaluk/februarytomarch2021#main-themes-for-concern-about-or-unwillingness-to-receive-a-covid-19-vaccine
   Google Scholar
• Mayr FB, Talisa VB, Shaikh O, et al. Effectiveness of homologous or heterologous COVID-19 boosters in veterans. N Engl J Med. 2022;386(14):1375–1377. doi: 10.1056/NEJMc2200415
   PubMed Web of Science ®Google Scholar
• Chalkias S, Harper C, Vrbicky K, et al. A bivalent omicron-containing booster vaccine against COVID-19. N Engl J Med. 2022;387(14):1279–1291. doi: 10.1056/NEJMoa2208343
   PubMed Web of Science ®Google Scholar
• Thompson SG, Higgins JPT. How should meta‐regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559–1573. doi: 10.1002/sim.1187
   PubMed Web of Science ®Google Scholar
• Melander H, Ahlqvist-Rastad J, Meijer G, et al. Evidence b(i)ased medicine–selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ [Internet]. 2003;326(7400):1171–1173. Available from: https://www.bmj.com/lookup/doi/10.1136/bmj.326.7400.1171
   PubMed Web of Science ®Google Scholar
• Bonhoeffer J, Kohl K, Chen R, et al. The brighton collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine. 2002;21(3–4):298–302. doi: 10.1016/S0264-410X(02)00449-8
   PubMed Web of Science ®Google Scholar